Insilico Medicine

Company ● Covered in 2 stories + Follow ✴ AI Graph LinkedIn

This profile is built automatically from TLDRocket coverage.

Signals

2 stories (new)

Media momentum

As of 10 Sep 2026 · Visible stories in the last 30 days, compared with the 30 days before.

2 sources

Source diversity

As of 10 Sep 2026 · Distinct publications behind this entity's visible coverage.

—

Release activity

As of 10 Sep 2026 · Model, product and open-source release events in the last 90 days whose coverage involves this entity.

—

Funding signals

As of 10 Sep 2026 · Funding and acquisition events in the last 90 days whose coverage involves this entity.

Sep 2026

Coverage span

As of 10 Sep 2026 · First to most recent month of TLDRocket coverage of this entity.

Management

updated 9 Sep 2026

Alex Zhavoronkov Founder & CEO
Frank Pun Head Of Insilico Hong Kong
Andy Min Xie Head Of Hr, VP
Sujata Rao Chief Medical Officer
Min Fang Managing Director of Healthcare
Jimmy Yen-Chu Lin CEO, Insilico Medicine Taiwan
Alex Aliper President
Donald Small Advisor
Michael Levitt Advisor
Alán Aspuru-Guzik Advisor
Klaus Witte Advisor
Charles Cantor Advisor

+ 3 more tracked

Latest developments

Insilico's co-CEO hopes 'we might have a chance to stop biological aging' after promising results from its fibrosis drug trial Fortune · 27

Insilico’s AI-designed drug made patients look biologically younger on six aging clocks Nature Publishing Group US · 1 day ago · 8

Timeline

Month Quarter Year

Q3 2026

Insilico Medicine reported early phase 2a trial results for its AI-designed fibrosis drug showing reductions in predicted biological age across multiple proteomic aging clocks Benchmark result

Relationships

People

Feng Ren employed by this company · 1 source

Every AI story that matters,
in your inbox by 8am.

TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.